COVID-19 Risk in Cancer Patients Receiving Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 403
Special Issue Editor
Interests: molecular pharmacology; cancer pharmacology; natural products; ethnomedicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In COVID-19 patients, pneumonitis is the leading cause of death and morbidity.
Pneumonitis, on the other hand, is a rare adverse event (AE) caused by immunotherapy (IMT); it occurs in between 2% and 5% of patients receiving IMT monotherapy and about 10% of patients receiving IMT combination therapy (anti-PD-1/PD-L1 + anti-CTLA-4).
Notably, while pneumonitis is not a common adverse event in IMT patients, it is associated with a high mortality rate.
In terms of immunotherapy, the main barrier is the poor performance in mimicking cancer, in addition to the prevention of COVID-19 infection, especially when compared to human immunological and biological factors. The following topics should be addressed to further reveal the ways in which one can overcome this problem:
- How to strengthen cancer immunotherapy treatment;
- How to create a collaborative process that incorporates both clinical and non-clinical aspects;
- How to improve cancer treatment for SARS-CoV-2 infected patients;
- How to improve the biological response of immunotherapy for complicated cancer microenvironments and immunotherapeutic administration (anti-PD-1/PD-L1 + anti-CTLA-4);
- How to improve the aspects of composition, structure, and surface–interface interactions to better mimic immunity during COVID-19 infection.
This article collection focuses on addressing underappreciated issues in the development of treatment strategies, new technologies, and new functional parameters that can better mimic human cancer immunotherapy.
The goal of this research topic is to cover prospective current and novel research on cancer immunotherapy and alternative medical treatment. It may cover (but is not limited to) the following topics:- Development of novel treatment agents with expected mechanism properties, biocompatibility, and immunotherapy support;
- Development of novel technologies for immunity booster (anti-PD-1/PD-L1 + anti-CTLA-4);
- Bioengineered IMT technologies and designs.
Dr. Arjun Singh
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- immunotherapy
- anti-PD-1
- IMT
- COVID-19
